DK3458067T3 - Behandling af neurologiske lidelser - Google Patents

Behandling af neurologiske lidelser Download PDF

Info

Publication number
DK3458067T3
DK3458067T3 DK17725862.1T DK17725862T DK3458067T3 DK 3458067 T3 DK3458067 T3 DK 3458067T3 DK 17725862 T DK17725862 T DK 17725862T DK 3458067 T3 DK3458067 T3 DK 3458067T3
Authority
DK
Denmark
Prior art keywords
treatment
neurological disorders
neurological
disorders
Prior art date
Application number
DK17725862.1T
Other languages
English (en)
Inventor
Denise Rageot
Paul Hebeisen
Florent Beaufils
Doriano Fabbro
Hoa Huu Phuc Nguyen
Wolfgang Löscher
Claudia Brandt
Petra Hillmann-Wullner
Alexander Markus Sele
Original Assignee
Univ Basel
Torqur Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Basel, Torqur Ag filed Critical Univ Basel
Application granted granted Critical
Publication of DK3458067T3 publication Critical patent/DK3458067T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53861,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14Ortho-condensed systems
    • C07D491/153Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK17725862.1T 2016-05-18 2017-05-17 Behandling af neurologiske lidelser DK3458067T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16170107 2016-05-18
PCT/EP2017/025136 WO2017198346A1 (en) 2016-05-18 2017-05-17 Treatment of neurological disorders

Publications (1)

Publication Number Publication Date
DK3458067T3 true DK3458067T3 (da) 2021-04-06

Family

ID=56024138

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17725862.1T DK3458067T3 (da) 2016-05-18 2017-05-17 Behandling af neurologiske lidelser

Country Status (25)

Country Link
US (3) US20190284178A1 (da)
EP (1) EP3458067B1 (da)
JP (1) JP6991158B2 (da)
KR (1) KR102472461B1 (da)
CN (1) CN109475560B (da)
AU (1) AU2017265383B2 (da)
CA (1) CA3022753C (da)
CY (1) CY1124051T1 (da)
DK (1) DK3458067T3 (da)
ES (1) ES2863250T3 (da)
HR (1) HRP20210477T1 (da)
HU (1) HUE053494T2 (da)
IL (1) IL263080B (da)
LT (1) LT3458067T (da)
MX (1) MX2018014168A (da)
PL (1) PL3458067T3 (da)
PT (1) PT3458067T (da)
RS (1) RS61655B1 (da)
RU (1) RU2765868C2 (da)
SG (1) SG11201809792TA (da)
SI (1) SI3458067T1 (da)
SM (1) SMT202100177T1 (da)
TW (1) TWI753912B (da)
WO (1) WO2017198346A1 (da)
ZA (1) ZA201807393B (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3458067T3 (pl) * 2016-05-18 2021-12-13 Torqur Ag Leczenie chorób neurologicznych
MX2018014167A (es) 2016-05-18 2019-08-16 Piqur Therapeutics Ag Tratamiento de lesiones de la piel.
SG11202004589SA (en) 2017-11-23 2020-06-29 Piqur Therapeutics Ag Treatment of skin disorders
KR20240008312A (ko) * 2021-04-09 2024-01-18 유니버시타트 바셀 Pi3k의 가역적 및 비가역적 공유 억제제로서의 트리아진 유도체
CN117396470A (zh) * 2021-04-09 2024-01-12 巴塞尔大学 作为pi3k的可逆和不可逆共价抑制剂的三嗪衍生物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
ES2459018T3 (es) * 2006-02-09 2014-05-07 Alba Therapeutics Corporation Formulaciones de efectores de la unión estrecha
TWI498332B (zh) 2006-04-26 2015-09-01 Hoffmann La Roche 作為pi3k抑制劑之嘧啶衍生物及相關製備方法、醫藥組合物、用途、套組及產物
EP2050749B1 (en) 2006-08-08 2017-11-22 Chugai Seiyaku Kabushiki Kaisha Pyrimidine derivative as pi3k inhibitor and use thereof
WO2008098058A1 (en) * 2007-02-06 2008-08-14 Novartis Ag Pi 3-kinase inhibitors and methods of their use
LT2294072T (lt) 2008-05-23 2017-06-12 Wyeth Llc Triazino junginiai, kaip p13 kinazės ir mtor inhibitoriai
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
MX364558B (es) 2013-10-04 2019-04-29 Univ Basel INHIBIDORES DE PI3K Y mTOR CONFORMACIONALMENTE RESTRINGIDOS.
MA40933A (fr) * 2014-11-11 2017-09-19 Piqur Therapeutics Ag Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
CA3022758C (en) 2016-05-18 2024-02-06 Piqur Therapeutics Ag Treatment of skin lesions
PL3458067T3 (pl) * 2016-05-18 2021-12-13 Torqur Ag Leczenie chorób neurologicznych
MX2018014167A (es) * 2016-05-18 2019-08-16 Piqur Therapeutics Ag Tratamiento de lesiones de la piel.

Also Published As

Publication number Publication date
EP3458067B1 (en) 2020-12-30
KR102472461B1 (ko) 2022-11-30
PT3458067T (pt) 2021-04-07
CY1124051T1 (el) 2022-05-27
RU2018140013A (ru) 2020-06-18
BR112018073579A2 (pt) 2019-03-19
HRP20210477T1 (hr) 2021-05-14
IL263080B (en) 2022-02-01
IL263080A (en) 2018-12-31
TW201808944A (zh) 2018-03-16
RU2018140013A3 (da) 2020-07-09
ES2863250T3 (es) 2021-10-11
RS61655B1 (sr) 2021-04-29
HUE053494T2 (hu) 2021-06-28
WO2017198346A1 (en) 2017-11-23
KR20190008294A (ko) 2019-01-23
AU2017265383B2 (en) 2022-07-28
NZ748601A (en) 2024-12-20
TWI753912B (zh) 2022-02-01
JP6991158B2 (ja) 2022-02-10
CA3022753C (en) 2024-09-24
US20240343718A1 (en) 2024-10-17
MX2018014168A (es) 2019-04-29
US11878972B2 (en) 2024-01-23
US20190284178A1 (en) 2019-09-19
SG11201809792TA (en) 2018-12-28
RU2765868C2 (ru) 2022-02-04
US20220135551A1 (en) 2022-05-05
SI3458067T1 (sl) 2021-07-30
ZA201807393B (en) 2023-10-25
LT3458067T (lt) 2021-04-26
AU2017265383A1 (en) 2018-12-13
PL3458067T3 (pl) 2021-12-13
BR112018073579A8 (pt) 2023-01-10
EP3458067A1 (en) 2019-03-27
CN109475560B (zh) 2023-05-02
CN109475560A (zh) 2019-03-15
CA3022753A1 (en) 2017-11-23
SMT202100177T1 (it) 2021-05-07
JP2019519507A (ja) 2019-07-11

Similar Documents

Publication Publication Date Title
IL285151A (en) Methods of treating fgf21-associated disorders
DK3570844T3 (da) Azolopyrimidin til behandlingen af kræftrelaterede lidelser
DK3185876T3 (da) Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser
DK3548061T3 (da) Behandling af neurologiske sygdomme
DK3261640T3 (da) 5ht-agonister til behandling af epilepsilidelser
DK3265085T3 (da) Fremgangsmåder til behandling af forstyrrelser med abnorme ufrivillige bevægelser
DK3134530T3 (da) Behandling af hyperbilirubinæmi
DK3777855T3 (da) Fremgangsmåder til behandling af fibrotiske sygdomme
IL262852A (en) Treatment of complement-mediated disorders
DK3506904T3 (da) Behandling af demens
DK3288577T3 (da) Adiponectin-peptidomimetika til behandling af øjenlidelser
DK3419622T3 (da) Behandling af neurodegenerativ øjensygdom med pridopidin
DK3458052T3 (da) Kombinationsbehandling af cancer
DK3192524T3 (da) Hgf præparat egnet til behandling af neurologiske lidelser
DK3439661T3 (da) Fremgangsmåder til behandling af øjenlidelser
DK3307267T3 (da) Behandling af multipel sklerose
DK3430143T3 (da) Inhibitorer af SRSF1 til behandlingen af neurodegenerative sygdomme
IL263080B (en) Treatment of neurological disorders
DK3848028T3 (da) Fremgangsmåder til behandling af øjenlidelser
DK3724173T3 (da) Forbindelser til behandling af neuromuskulære lidelser
DK3302573T3 (da) Sammensætning til behandlingen af hjernelæsioner
DK3200828T3 (da) Intranasale sammensætninger til behandling af neurologiske og neurodegenerative sygdomme og forstyrrelser
IL280227A (en) Arimoclomol for treating glucocerebrosidase associated disorders
DK3432895T3 (da) Blodpladepelletlysat til anvendelse til behandling af neurologiske forstyrrelser
GB201607388D0 (en) Treatment of impulsivity-related disorders